Want to see HK:1498 full AI Analyst Report?
PuraPharm Corp. Ltd. (1498) Ratios
PuraPharm Corp. Ltd. Ratios
HK:1498's free cash flow for Q2 2026 was $-12.62M. For the 2026 fiscal year, HK:1498's free cash flow was decreased by $-1.47M and operating cash flow was $-11.15M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.47 | 0.55 | 0.61 | 0.73 | 0.92 |
| Quick Ratio | 0.27 | 0.30 | 0.30 | 0.44 | 0.62 |
| Cash Ratio | 0.04 | 0.03 | 0.04 | 0.16 | 0.09 |
| Solvency Ratio | 0.02 | 0.00 | -0.08 | -0.09 | -0.09 |
| Operating Cash Flow Ratio | 0.06 | 0.21 | 0.14 | 0.10 | -0.06 |
| Short-Term Operating Cash Flow Coverage | 0.11 | 0.42 | 0.26 | 0.16 | -0.10 |
| Net Current Asset Value | $ -333.50M | $ -336.09M | $ -341.16M | $ -271.19M | $ -192.27M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.51 | 0.51 | 0.50 | 0.49 | 0.44 |
| Debt-to-Equity Ratio | 2.69 | 3.27 | 2.77 | 1.95 | 1.32 |
| Debt-to-Capital Ratio | 0.73 | 0.77 | 0.73 | 0.66 | 0.57 |
| Long-Term Debt-to-Capital Ratio | 0.30 | 0.45 | 0.35 | 0.16 | 0.19 |
| Financial Leverage Ratio | 5.32 | 6.44 | 5.51 | 3.94 | 3.00 |
| Debt Service Coverage Ratio | 0.10 | 0.04 | -0.09 | -0.11 | -0.10 |
| Interest Coverage Ratio | -1.45 | -1.24 | -1.88 | -2.67 | 0.65 |
| Debt to Market Cap | 2.18 | 1.56 | 1.10 | 0.91 | 1.57 |
| Interest Debt Per Share | 0.89 | 0.98 | 1.14 | 1.34 | 1.42 |
| Net Debt to EBITDA | 11.66 | 20.23 | -15.38 | -8.55 | -11.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 53.60% | 53.69% | 53.24% | 58.16% | 63.96% |
| EBIT Margin | -4.83% | -4.78% | -18.41% | -21.20% | -13.67% |
| EBITDA Margin | 8.42% | 4.54% | -6.47% | -10.34% | -6.07% |
| Operating Profit Margin | -8.92% | -7.70% | -12.68% | -14.40% | 2.67% |
| Pretax Profit Margin | -10.24% | -7.55% | -25.15% | -26.60% | -17.77% |
| Net Profit Margin | -10.48% | -9.28% | -26.07% | -26.83% | -18.48% |
| Continuous Operations Profit Margin | -10.48% | -9.28% | -26.07% | -26.83% | -18.48% |
| Net Income Per EBT | 102.36% | 122.92% | 103.68% | 100.87% | 104.00% |
| EBT Per EBIT | 114.76% | 98.02% | 198.34% | 184.78% | -665.18% |
| Return on Assets (ROA) | -5.08% | -4.95% | -12.57% | -11.83% | -10.11% |
| Return on Equity (ROE) | -26.99% | -31.87% | -69.23% | -46.54% | -30.35% |
| Return on Capital Employed (ROCE) | -13.99% | -13.09% | -18.90% | -18.37% | 3.26% |
| Return on Invested Capital (ROIC) | -6.02% | -6.02% | -8.67% | -8.27% | 1.83% |
| Return on Tangible Assets | -5.79% | -5.32% | -13.41% | -12.83% | -10.85% |
| Earnings Yield | -23.69% | -16.31% | -30.17% | -23.80% | -38.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.96 | 6.65 | 3.60 | 3.40 | 2.20 |
| Payables Turnover | 1.83 | 1.34 | 1.30 | 1.36 | 1.69 |
| Inventory Turnover | 1.57 | 1.43 | 1.08 | 0.98 | 1.19 |
| Fixed Asset Turnover | 0.95 | 1.08 | 1.03 | 1.04 | 1.34 |
| Asset Turnover | 0.48 | 0.53 | 0.48 | 0.44 | 0.55 |
| Working Capital Turnover Ratio | -1.42 | -1.72 | -2.03 | -3.83 | -34.12 |
| Cash Conversion Cycle | 93.92 | 37.07 | 157.33 | 210.41 | 256.80 |
| Days of Sales Outstanding | 61.25 | 54.93 | 101.27 | 107.42 | 166.03 |
| Days of Inventory Outstanding | 232.14 | 254.87 | 336.92 | 371.48 | 306.75 |
| Days of Payables Outstanding | 199.47 | 272.72 | 280.86 | 268.49 | 215.98 |
| Operating Cycle | 293.39 | 309.79 | 438.19 | 478.90 | 472.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.07 | 0.26 | 0.20 | 0.17 | -0.10 |
| Free Cash Flow Per Share | 0.06 | 0.23 | 0.15 | 0.11 | -0.12 |
| Dividend Paid and CapEx Coverage Ratio | 10.06 | 7.02 | 3.68 | 2.80 | -6.00 |
| Capital Expenditure Coverage Ratio | 10.06 | 7.02 | 3.68 | 2.80 | -6.00 |
| Operating Cash Flow Coverage Ratio | 0.08 | 0.29 | 0.19 | 0.13 | -0.07 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.27 | 0.20 | 0.15 | -0.06 |
| Free Cash Flow Yield | 17.28% | 41.04% | 16.48% | 8.37% | -14.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.22 | -6.13 | -3.31 | -4.20 | -2.62 |
| Price-to-Sales (P/S) Ratio | 0.44 | 0.57 | 0.86 | 1.13 | 0.48 |
| Price-to-Book (P/B) Ratio | 1.14 | 1.95 | 2.29 | 1.96 | 0.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 5.79 | 2.44 | 6.07 | 11.94 | -6.95 |
| Price-to-Operating Cash Flow Ratio | 5.21 | 2.09 | 4.42 | 7.67 | -8.11 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | 0.09 | 0.33 | 1.30 | 0.01 |
| Enterprise Value Multiple | 16.91 | 32.76 | -28.74 | -19.45 | -19.77 |
| Enterprise Value | 478.63M | 568.25M | 756.24M | 901.21M | 791.21M |
| EV to EBITDA | 16.91 | 32.76 | -28.74 | -19.45 | -19.77 |
| EV to Sales | 1.42 | 1.49 | 1.86 | 2.01 | 1.20 |
| EV to Free Cash Flow | 18.63 | 6.37 | 13.05 | 21.31 | -17.24 |
| EV to Operating Cash Flow | 16.78 | 5.46 | 9.50 | 13.69 | -20.12 |
| Tangible Book Value Per Share | 0.12 | 0.16 | 0.25 | 0.46 | 0.81 |
| Shareholders’ Equity Per Share | 0.31 | 0.28 | 0.39 | 0.65 | 1.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | -0.22 | -0.04 | -0.01 | -0.04 |
| Revenue Per Share | 0.80 | 0.97 | 1.03 | 1.14 | 1.68 |
| Net Income Per Share | -0.08 | -0.09 | -0.27 | -0.30 | -0.31 |
| Tax Burden | 1.02 | 1.23 | 1.04 | 1.01 | 1.04 |
| Interest Burden | 2.12 | 1.58 | 1.37 | 1.25 | 1.30 |
| Research & Development to Revenue | 0.04 | 0.03 | 0.00 | 0.05 | 0.04 |
| SG&A to Revenue | 0.61 | 0.58 | 0.42 | 0.35 | 0.26 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Income Quality | -0.83 | -2.93 | -0.75 | -0.55 | 0.32 |
Currency in HKD